DK0708922T3 - Identificering af ligander ved selektiv amplifikation af celler transfekteret med receptorer - Google Patents

Identificering af ligander ved selektiv amplifikation af celler transfekteret med receptorer

Info

Publication number
DK0708922T3
DK0708922T3 DK94923478T DK94923478T DK0708922T3 DK 0708922 T3 DK0708922 T3 DK 0708922T3 DK 94923478 T DK94923478 T DK 94923478T DK 94923478 T DK94923478 T DK 94923478T DK 0708922 T3 DK0708922 T3 DK 0708922T3
Authority
DK
Denmark
Prior art keywords
ligands
receptors
identification
cells transfected
selective amplification
Prior art date
Application number
DK94923478T
Other languages
Danish (da)
English (en)
Inventor
Mark Robert Brann
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Application granted granted Critical
Publication of DK0708922T3 publication Critical patent/DK0708922T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2334/00—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
    • C12Q2334/10—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases p-Nitrophenol derivatives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK94923478T 1993-07-13 1994-07-13 Identificering af ligander ved selektiv amplifikation af celler transfekteret med receptorer DK0708922T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9169493A 1993-07-13 1993-07-13
PCT/US1994/007900 WO1995002823A1 (fr) 1993-07-13 1994-07-13 Identification de ligands par amplification selective de cellules transfectees avec des recepteurs

Publications (1)

Publication Number Publication Date
DK0708922T3 true DK0708922T3 (da) 1999-09-27

Family

ID=22229179

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94923478T DK0708922T3 (da) 1993-07-13 1994-07-13 Identificering af ligander ved selektiv amplifikation af celler transfekteret med receptorer

Country Status (13)

Country Link
US (3) US5707798A (fr)
EP (1) EP0708922B1 (fr)
JP (1) JP3102571B2 (fr)
KR (1) KR100272459B1 (fr)
AT (1) ATE177535T1 (fr)
AU (1) AU679253B2 (fr)
CA (1) CA2167048C (fr)
DE (1) DE69417037T2 (fr)
DK (1) DK0708922T3 (fr)
ES (1) ES2129658T3 (fr)
IL (1) IL110298A (fr)
NZ (1) NZ269442A (fr)
WO (1) WO1995002823A1 (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69527585T2 (de) * 1994-06-08 2003-04-03 Affymetrix, Inc. Verfahren und Vorrichtung zum Verpacken von Chips
US6287850B1 (en) * 1995-06-07 2001-09-11 Affymetrix, Inc. Bioarray chip reaction apparatus and its manufacture
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
AU4941796A (en) * 1995-02-28 1996-09-18 Beiersdorf-Lilly Gmbh Use of moxonidine for the treatment of atherosclerosis
ES2237764T3 (es) * 1995-03-03 2005-08-01 Syngenta Participations Ag Control de la expresion genica en plantas por transactivacion mediada por un receptor en presencia de un ligando quimico.
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
KR19990064155A (ko) 1995-10-10 1999-07-26 더블류. 하링, 지. 보이롤 수용체 매개된 트랜스활성화에 의해 식물에서 유전자 발현을조절하기 위한 화학적 리간드로서의유충 호르몬 또는 이의효능제
JP2001504321A (ja) * 1996-06-17 2001-04-03 マイクロサイド・ファーマシューティカルズ・インコーポレーテッド 微生物菌株プールを用いるスクリーニング方法
US5985584A (en) * 1997-02-19 1999-11-16 American Cyanamid Company Method to identify plant proteins that function in G protein coupled systems and compositions therefor
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
EP0887081B1 (fr) * 1997-06-27 2003-04-23 Smithkline Beecham Corporation Kinase régulée par les glucocorticoides du sérum humain, une cible pour maladies rénales chroniques et néphropaties diabétiques
EP1069917A4 (fr) * 1998-03-20 2005-02-09 Genzyme Corp Nouvelles paires complementaires de recepteurs /ligands et immunotherapie adoptive les utilisant
EP1070257A2 (fr) * 1998-04-06 2001-01-24 Lerner Pharmaceuticals, Inc. Biocapteurs par evolution dirigee
US6277588B1 (en) * 1998-05-01 2001-08-21 Tel Aviv University Screening of cell populations
AU2196200A (en) * 1998-12-17 2000-07-03 Johns Hopkins University School Of Medicine, The Olfactory receptor expression libraries and methods of making and using them
US6720139B1 (en) 1999-01-27 2004-04-13 Elitra Pharmaceuticals, Inc. Genes identified as required for proliferation in Escherichia coli
US20050148018A1 (en) 1999-10-07 2005-07-07 David Weiner Methods of identifying inverse agonists of the serotonin 2A receptor
WO2001034810A2 (fr) 1999-11-09 2001-05-17 Elitra Pharmaceuticals, Inc. Genes indispensables a une proliferation microbienne et antisens a cet egard
AU3263101A (en) * 1999-11-24 2001-06-04 Millennium Pharmaceuticals, Inc. Expression cloning method
EP1255854A2 (fr) * 2000-02-01 2002-11-13 Agy Therapeutics, Inc. Interaction du recepteur de n-methyl-d-aspartate et de la tyrosine phosphatase
US20030092071A1 (en) * 2000-02-01 2003-05-15 Jasna Jerecic Interaction of NMDA receptor with protein tyrosine phosphatase
US20030013140A1 (en) * 2000-02-08 2003-01-16 Tadayoshi Taniyama Method of detecting ligand or ligand-like low-molecular weight compound
IL151164A0 (en) 2000-03-06 2003-04-10 Acadia Pharm Inc Azacyclic compounds for use in the treatment of serotonin related diseases
GB2360282A (en) * 2000-03-17 2001-09-19 Bioinvent Int Ab Making and using micro-arrays of biological materials
DE60109148T2 (de) * 2000-04-28 2006-01-05 Acadia Pharmaceuticals Inc., San Diego Muscarinrezeptoren
CN1333213A (zh) * 2000-07-07 2002-01-30 上海博德基因开发有限公司 一种新的多肽——细胞信号传导蛋白My D24.09和编码这种多肽的多核苷酸
US6576422B1 (en) 2000-10-17 2003-06-10 Rohm And Haas Company Method for identifying products employing gene expression
US6977152B2 (en) * 2001-09-07 2005-12-20 Virtual Arrays, Inc. Biological assays using coded RNA reporters
US6951849B2 (en) * 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
CA2457647A1 (fr) * 2001-10-02 2003-04-10 Acadia Pharmaceuticals, Inc. Derives de benzimidazolidinone utilises comme agents muscariniques
US7550459B2 (en) * 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
EP1461318B9 (fr) * 2001-12-28 2005-12-28 Acadia Pharmaceuticals Inc. Analogues de tetrahydroquinoline utiles comme agonistes muscariniques
WO2003057698A2 (fr) * 2001-12-28 2003-07-17 Acadia Pharmaceuticals, Inc. Composes spiroazacycliques utilises comme modulateurs du recepteur de monoamine
US20030170744A1 (en) * 2002-03-05 2003-09-11 Beske Oren E. Multiplexed analysis of cellular responses using endogenous reporter genes
US7199844B2 (en) * 2002-05-28 2007-04-03 Rfstream Corporation Quadratic nyquist slope filter
WO2003104216A1 (fr) * 2002-06-10 2003-12-18 Acadia Pharmaceuticals Inc. Modulateurs du recepteur de l'urotensine ii
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
RU2320646C2 (ru) * 2002-06-24 2008-03-27 Акадиа Фармасьютикалз Инк. N-замещенные производные пиперидина в качестве агентов серотонинового рецептора
US7253186B2 (en) * 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
DE10233516A1 (de) 2002-07-23 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Identifizierung von Substanzen
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
US6884473B2 (en) * 2002-12-24 2005-04-26 Macronix International Co., Ltd. Method for fabricating metal silicide
CN1816524B (zh) * 2003-01-16 2012-06-27 阿卡蒂亚药品公司 用于神经退行性疾病的治疗的选择性五羟色胺2a/2c受体反向激动剂
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
KR20050092123A (ko) * 2003-01-23 2005-09-20 아카디아 파마슈티칼스 인코포레이티드 Ｎ-데스메틸클로자핀의 인간의 신경정신성 질환의 치료용도
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
MXPA05008802A (es) * 2003-02-19 2005-10-18 Acadia Pharm Inc Un procedimiento de andamio combinacional para los farmacoforos de ligandos para receptores de urotensina ii y somatostatina 5.
KR20050112116A (ko) * 2003-03-28 2005-11-29 아카디아 파마슈티칼스 인코포레이티드 통증 관리를 위한 무스카린성 ｍ1 리셉터 작용제
US20070196865A1 (en) * 2003-09-16 2007-08-23 Molecular Devices Corporation Methods Of Screening Compositions For G Protein-Coupled Receptors Aganist Agonists
US20050136444A1 (en) * 2003-09-25 2005-06-23 Scully Audra L. Treating neuropathic pain with neuropeptide FF receptor 2 agonists
JP2007536904A (ja) * 2003-11-03 2007-12-20 アカディア ファーマシューティカルズ，インコーポレーテッド ｒａｐ−ｒａｓキメラタンパク質を用いるＧタンパク質共役受容体の高スループット機能アッセイ
JP2007534656A (ja) * 2003-12-22 2007-11-29 アカディア ファーマシューティカルズ，インコーポレーテッド ムスカリンアゴニストとしてのアミノ置換ジアリール［ａ，ｄ］シクロヘプテン類似体および精神神経疾患の治療方法
EP1756070A2 (fr) * 2004-04-01 2007-02-28 Acadia Pharmaceuticals Inc. Formes cristallines de n-desmethylclozapine
US7825265B2 (en) * 2004-05-04 2010-11-02 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
US20070004679A1 (en) * 2004-05-17 2007-01-04 Nathalie Schlienger Androgen receptor modulators and methods of treating disease using the same
US7268232B2 (en) * 2004-05-17 2007-09-11 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) * 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US7790899B2 (en) * 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
BRPI0516063A (pt) * 2004-09-27 2008-08-19 Acadia Pharm Inc sìntese de n-(4-fluorbenzil)-n-(1-metilpiperidin-4-il)-n'-(4-(2-metilp ropi-loxi)fenilmetil)carbamida e seu sal tartarato e formas cristalinas
JP2008520244A (ja) * 2004-11-19 2008-06-19 アカディア ファーマシューティカルズ インコーポレイテッド ホルモン核内受容体のリガンドの同定方法
CN101119993B (zh) 2005-01-10 2015-03-04 阿卡蒂亚药品公司 作为选择性雄激素受体调节剂的氨基苯基衍生物
US20080318960A1 (en) * 2005-05-26 2008-12-25 Ethan Burstein PAR2-modulating compounds and their use
US20070123508A1 (en) * 2005-05-27 2007-05-31 Roger Olsson PAR2-modulating compounds and their use
EP1937614A1 (fr) * 2005-10-17 2008-07-02 Arcadia Pharmaceuticals Inc. Reactions de couplage croise catalyse au fer de derives d'imidoyle
US20070105819A1 (en) * 2005-10-17 2007-05-10 Roger Olsson CB-1 modulating compounds and their use
WO2007053618A1 (fr) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Promédicaments d'agonistes muscariniques et méthodes de traitement de troubles neuropsychiatriques
US20070213359A1 (en) * 2005-12-30 2007-09-13 Acadia Pharmaceuticals Inc. Bicyclic-nitrogen compounds as modulators of ghrelin receptor and uses thereof
US7655396B1 (en) 2006-09-29 2010-02-02 Allergan, Inc. Methods for detecting receptor modulator activity
JP2010513551A (ja) * 2006-12-18 2010-04-30 アラーガン インコーポレイテッド 胃腸疾患の治療方法および組成物
PL2134330T3 (pl) 2007-03-19 2013-10-31 Acadia Pharm Inc Kombinacje odwrotnych agonistów i antagonistów 5-HT2A z antypsychotykami
WO2009039460A2 (fr) * 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. Co-administration de pimavansérine avec d'autres agents
WO2009128058A1 (fr) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Produits psycho-pharmaceutiques
EP2291181B9 (fr) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Utilisation de la captodiamine pour le traitement des symptômes de la dépression
US20120196302A1 (en) * 2008-10-07 2012-08-02 Lai Lee Jene Detecting method
WO2010111353A1 (fr) 2009-03-25 2010-09-30 Acadia Pharmaceuticals, Inc. Dérivés de pipéridine n-substitués en tant qu'agents spécifiques des récepteurs de la sérotonine
WO2011017564A2 (fr) * 2009-08-06 2011-02-10 California Institute Of Technology Identification et utilisation de composés dans le traitement de la douleur persistante
US20110105389A1 (en) 2009-10-30 2011-05-05 Hoveyda Hamid R Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same
WO2013049725A2 (fr) * 2011-09-30 2013-04-04 Tufts University Procédés d'utilisation de l'activation du récepteur a1 de l'adénosine pour le traitement de la dépression
RU2015144155A (ru) 2013-03-15 2017-04-24 Акадиа Фармасьютикалз Инк. Мускариновые агонисты
CA2937107C (fr) 2014-01-17 2020-12-22 Cornell University Methodes de traitement d'etats pathologiques apparentes a un syndrome metabolique a l'aide d'agonistes du recepteur de l'acide retinoique
SI3325444T1 (sl) 2015-07-20 2021-11-30 Acadia Pharmaceuticals Inc. Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (fr) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Association de pimavansérine et de modulateurs du cytochrome p450
WO2017180589A1 (fr) 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Dérivés de kétamine deutérés
US11464768B2 (en) 2016-12-20 2022-10-11 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
EP3615028A1 (fr) 2017-04-28 2020-03-04 Acadia Pharmaceuticals Inc. Pimavansérine pour le traitement d'un trouble de contrôle des impulsions
WO2019040105A2 (fr) 2017-08-21 2019-02-28 Acadia Pharmaceuticals Inc. Composés, sels de ces composés et procédés pour le traitement de maladies
EP3672960A2 (fr) 2017-08-21 2020-07-01 Acadia Pharmaceuticals Inc. Composés, sels associés et méthodes de traitement de maladies
CN117466803A (zh) 2017-08-21 2024-01-30 阿卡蒂亚药品公司 化合物、其盐和用于治疗疾病的方法
US20210077479A1 (en) 2017-08-30 2021-03-18 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
EP3806839B1 (fr) 2018-06-14 2024-08-07 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Agoniste du récepteur de l'acide rétinoïque beta2 avec des effets cardioprotecteurs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5462856A (en) * 1990-07-19 1995-10-31 Bunsen Rush Laboratories, Inc. Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
US5401629A (en) * 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
ES2157197T3 (es) * 1990-09-13 2001-08-16 Univ Duke Expresion de receptores acoplados a una proteina g en levadura.
AU685054C (en) * 1992-05-14 2003-02-27 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy

Also Published As

Publication number Publication date
ES2129658T3 (es) 1999-06-16
DE69417037T2 (de) 1999-10-21
JP3102571B2 (ja) 2000-10-23
IL110298A (en) 1999-04-11
US5955281A (en) 1999-09-21
AU679253B2 (en) 1997-06-26
NZ269442A (en) 1997-06-24
IL110298A0 (en) 1994-10-21
AU7333094A (en) 1995-02-13
EP0708922B1 (fr) 1999-03-10
KR100272459B1 (ko) 2000-11-15
DE69417037D1 (de) 1999-04-15
US5912132A (en) 1999-06-15
JPH09500023A (ja) 1997-01-07
CA2167048A1 (fr) 1995-01-26
US5707798A (en) 1998-01-13
WO1995002823A1 (fr) 1995-01-26
EP0708922A1 (fr) 1996-05-01
ATE177535T1 (de) 1999-03-15
CA2167048C (fr) 2001-09-25

Similar Documents

Publication Publication Date Title
DK0708922T3 (da) Identificering af ligander ved selektiv amplifikation af celler transfekteret med receptorer
DK1000345T3 (da) Fremgangsmåde og apparat til dannelse af referencer for fluorescensintensitetssignaler
DK1681A (da) Femgangsmaade til fremstilling af platin (iv)-diamin-komplekser
DE3885220D1 (de) Toilette mit Vorrichtung zum Feststellen der Zusammensetzung von Urin.
DK301986A (da) Fremgangsmaade til fremstilling af 1-hydroxyvitamin-d-forbindelser
DE3582740D1 (de) Spezifischer bindungstest unter verwendung von anti-g6pdh als markierungsmittel.
DK357081A (da) Fremgangsmaade til fremstilling af heterocycliske forbindelser
DK229588D0 (da) Fremgangsmaade til foring af en eksisterende roerledning
DK203881A (da) Anlaeg til maaling af octantallet
AT375367B (de) Verfahren zur herstellung von als histamin h2-rezeptor-antagonisten wirkenden nitroverbindungen
DK0804736T3 (da) Ultrafølsom metode til bestemmelse af hjerte-troponin I
DK0393304T3 (da) Fremgangsmåde til foring af et underjordisk ledningsrør
DK50981A (da) Sprededyvel til forankring i konisk indefter udvidede borehuller
DK311881A (da) Elektrokemisk fremgangsmaade til syntetisering af organiske forbindelser
DK396083A (da) Fremgangsmaade til montering af balkoner
DE3583626D1 (de) Teststueck zum nachweis von nitrit.
DK576982A (da) Apparat til indfoering af forskalling i borehul
DK59881A (da) Eksplosionsdrevet apparat til inddrivning af bolte
DK142381A (da) Fremgangsmaade til fremstilling af substituerede triarylthiazolforbindelser
DK63885A (da) Braender til forbraending af pulverformet braendsel
DE3582085D1 (de) Vorrichtung zum feststellen der tonerdichte.
DK28598A (da) Fremgangsmåde til at regulere følsomheden af en mikrosensor samt mikrosensor, der gør brug af fremgangsmåden
DE69111016D1 (de) Zusammensetzung von Agenzien zum Nachweis einer Redox-Reaktion.
DK190385D0 (da) Fremgangsmaade til fremstilling af cephalosporinforbindelser
DK163802C (da) Fremgangsmaade til toer-rensning af roeggas fra forbraending af affaldsmateriale, der er i hovedsagen ikke-metallisk shredderaffald